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Chemotherapy-induced alopecia (CIA) is a frequent side effect of systemic antineoplastic therapy for cancer. It occurs when chemotherapy drugs such as taxanes, anthracyclines, and alkylating agents target rapidly dividing keratinocytes cells, damaging the hair follicle and resulting in CIA ([@A13]). Although it is not life-threatening and is often reversible, CIA is frequently described as the most distressing side effect of chemotherapy ([@A7]). McGarvey, Baum, Pinkerton, and Rogers ([@A10]) found half of female cancer survivors considered CIA to be the most upsetting side effect of antineoplastic therapy. Chemotherapy-induced alopecia affects 65% of individuals receiving chemotherapy, with up to 8% refusing treatment due to fear of developing this side effect ([@A21]). Ms. X is an example of a patient whose identity was impacted by the potential body image change of alopecia. For young adults with cancer, body image and how they look and feel about themselves can be particularly important given that they may be starting careers and looking for future partners.

Scalp cooling is reemerging in the United States due to the fact that health-care professionals are realizing the impact alopecia has on patients' psychosocial and emotional well-being ([@A15]). Scalp cooling works by causing vaso-constriction, therefore limiting the exposure of the hair follicles to chemotherapy ([@A16]). Sensor-controlled, machine-based scalp cooling has been demonstrated to be effective in reducing CIA in the majority of patients receiving chemotherapy for breast cancer; however, it is not yet used routinely in the United States ([@A2]; [@A5]; [@A22]; [@A28]). Manual scalp cooling systems are also available for use. Scalp cooling has only recently been approved by the US Food and Drug Administration (FDA) in the United States and is not yet widely reimbursed by third-party payers. However, scalp cooling has been available for more than a decade in Europe and is routinely used by clinicians in the United Kingdom and the Netherlands ([@A16]). The purpose of this paper is to describe the options and logistics of scalp cooling using a case study approach.

HISTORY OF SCALP COOLING
========================

Scalp cooling dates back more than 30 years and has been studied with more frequency in recent years. Until recent trials were published, scalp cooling had not been as widely used in the United States as compared to Europe ([@A17]). When first introduced in the United States, scalp cooling did not gain popularity, perhaps due to the disappointing efficacy in the older manual caps. Physicians and nurses were also concerned about the risk of scalp metastasis as a result of the decreased amount of chemotherapy delivered to the scalp ([@A19]).

In a trial of scalp cooling conducted at five medical centers in the United States by Rugo and colleagues ([@A18]), 122 women diagnosed with breast cancer were randomized to receive either adjuvant or neoadjuvant chemotherapy with or without machine-based scalp cooling. Two years of follow-up indicated no evidence of scalp metastasis, and follow-up will continue for 5 years ([@A19]).

In a larger European retrospective study, Lemieux and colleagues ([@A9]) studied 1,370 breast cancer patients receiving chemotherapy who used scalp cooling and compared them to women who were not using scalp cooling. They found no negative effect on long-term survival ([@A9]).

In an examination of a sample of women, van den Hurk and colleagues ([@A27]) found an incidence of 1% or less of scalp metastasis in breast cancer patients receiving paclitaxel, doxorubicin, and cyclophosphamide, compared to a 3% incidence of scalp metastasis in women with breast cancer who did not use scalp cooling. The study by Lemieux and colleagues ([@A9]) supported the hypothesis that there is no negative impact on overall survival for women who use scalp cooling.

Lemieux and colleagues ([@A9]) followed women for a period of 5 to 6 years. Because the highest incidence of breast cancer recurrence occurs 5 years after treatment, this time point is often chosen as a study endpoint. These studies led to the FDA approving one machine-based scalp cooling mechanism in 2015 and 2017. Devices currently available in the United States are briefly described in [Table 1](#T1){ref-type="fig"}. Scalp cooling is emerging as an option for patients in the United States who are concerned about reducing hair loss during their antineoplastic therapy ([@A16]).

PATIENT SELECTION
=================

Research on the effects of scalp cooling has focused mainly on the breast cancer population. Scalp cooling is not appropriate for every patient undergoing antineoplastic therapy. Patients with hematologic cancers associated with high levels of circulating tumor cells, such as leukemias and lymphomas, are not eligible. Cold agglutinin disease, cold sensitivity, cryoglobulinemia, cryofibrinogenemia, and cold urticaria are also considered to be contraindications for scalp cooling. Those who have central nervous system or scalp metastases, head and neck cancer, squamous cell or small cell cancer of the lung, patients currently receiving or with a history of radiation therapy to the brain, or who require treatment with bone marrow ablating chemotherapy, are also not candidates ([@A14]; [@A25]). Scalp cooling is less successful in older adults due to a diminished ability to vasoconstrict when exposed to cold ([@A26]). Patients with a large volume of hair or very thick hair, menopausal status, nicotine use, of certain ethnicities, and other medication use are at risk for decreased efficacy ([@A20]).

CHEMOTHERAPY
============

The majority of published evidence to support scalp cooling focuses on regimens used for breast cancer. The chemotherapy regimens that have been closely studied in the United States in scalp cooling trials include regimens using taxanes and anthracyclines. Several studies revealed higher rates of hair preservation with weekly taxane vs. every-21-day paclitaxel ([@A4]; [@A12]).

In the Scalp Cooling Alopecia Prevention (SCALP) randomized trial of 142 women receiving a taxane, anthracycline, or both, investigators saw a 59% higher rate of hair retention with scalp cooling ([@A12]). This hair retention rate was higher than that found in previous studies. Other studies that have been done in the United States using only taxane-containing regimens showed similar results, with a 66.3% rate of hair retention with scalp cooling ([@A12]). Two randomized studies completed in the United States have shown that scalp cooling is effective in preventing CIA in primary breast cancer treated with taxane-based chemotherapy, whereas little effect has been found in those also treated with doxorubicin ([@A12]; [@A17]). However, in a randomized trial that took place in Germany, patients exposed to anthracyclines did not compare unfavorably in terms of CIA, which may be attributable to the exclusive use of epirubicin instead of doxorubicin ([@A23]). Alopecia in triplet regiments is unavoidable and therefore scalp cooling should not be used. As scalp cooling becomes more popular in the United States, there is a potential for patients to make chemotherapy choices based on the ability to preserve their hair with scalp cooling ([@A12]). Ms. X chose weekly paclitaxel treatments based on her own research that suggested that this treatment schedule is associated with less hair loss. With the recent FDA approval of the expanded use of cooling caps for all solid tumor cancers, more patients will have the option to attempt to avoid CIA with scalp cooling ([@A25]).

SIDE EFFECTS OF SCALP COOLING
=============================

There are several common side effects reported with scalp cooling, which include a feeling of intense cold (27%--39%), headache (12%--24%), dizziness (20%), and boredom (11%--27%; [@A1]; [@A11]).

LOGISTICS OF SCALP COOLING
==========================

Patients must be evaluated by a provider to determine whether they are eligible for scalp cooling. If eligible, the patient ideally should be offered the option of manual vs. machine-based scalp cooling if both scenarios are available. If reimbursement is available, the insurance company may dictate which approach may be covered, which may affect patient decision-making. Appropriate education specific to each patient should be provided by treatment center staff as well as the cap provider/company. The responsibility for fitting the cap and preprocedure education may be shared by the treatment center and cap manufacturer. Often, the manufacturer carries the bulk of the responsibility as well as handling payment, and may refer to patient resources to assist with payment, some of which are outlined in [Table 2](#T2){ref-type="fig"}. It is important for the patient and family to understand their role in scalp cooling and the possibility that scalp cooling may not lead to the retention of 100% of hair. Ms. X used a brand of manual cold cap that requires the use of dry ice to keep the scalp cool. With the particular brand of cap she chose, the cap must be changed every 20 to 30 minutes, thus requiring her caregiver to be present throughout the treatment to change the caps. In this instance, Ms. X's caregiver had to bring multiple caps in a cooler on dry ice to each treatment.
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Unfortunately, scalp cooling is not routinely covered by insurance for patients in the United States ([@A3]; [@A14]). Costs of scalp cooling vary. Patients make arrangements directly with the company, which assists with fitting, and patients may be eligible for financial support for scalp cooling. van den Hurk ([@A26]) reported that in the Netherlands, the mean cost of scalp cooling was \$213.21 per patient per hospital visit, with \$109.52 in equipment cost and \$103.69 in nursing care costs. The cost of scalp cooling in the United States has not been reported but may range from \$1,500 to \$3,000 without financial assistance, depending on the number of chemotherapy treatments and the brand of cap used ([@A3]; [@A14]). Ms. X shared with us that she paid \$3,000 out of pocket for the rental of the Penguin cap for the 6 months of treatment and \$1,800 for the dry ice for the same length of time. This does not include the lost wages of her caregiver, who had to take off work each week to be at her treatments.

On treatment days, following the manufacturer's instructions, the patient's scalp is usually cooled for 30 minutes before infusion, during the infusion of chemotherapy, and for a period of time after chemotherapy, depending on the treatment regimen being given. The length of time required for scalp cooling after infusion is under investigation and varies by type of treatment given ([@A8]). The treatment center caring for the patient needs to consider how to accommodate the patient before and after treatment while cooling, when chemotherapy is not infusing. Chemotherapy administration time spent in the infusion chair or bed needs to be used as effectively as possible to promote throughput in the infusion clinic, while at the same time ensuring patient comfort. For this reason, some treatment centers choose to have a pre- and postchemotherapy treatment area for patients to cool their scalps. If a center or clinic opts to use a scalp cooling machine, more than one machine may need to be made available so the patient can detach from the treatment area machine, move to the posttreatment area, and reattach to a machine within a short period of time. Manufacturer guidelines suggest the maximum time (e.g., 10 minutes) a patient may be detached from the machine before the cap starts to warm up and vasodilation can occur, which allows chemotherapy to reach the follicles and cause CIA.

Some centers may choose to charge a facility fee to cover the cost of a cap fitting visit if applicable (depending on the brand of cap used), and to provide care to the patients who need assistance changing caps and need to be monitored while cooling before or after therapy. Patients may also choose to privately hire a \"capper,\" a person trained to change manual caps at intervals during therapy.
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PATIENT RESOURCES
=================

There are resources for patients who may seek to secure financial assistance to pay for scalp cooling. One of these is HairtoStay (hairtostay.org), a nonprofit organization that offers need-based grants to help patients. Another organization is The Rapunzel Project (rapunzelproject.org), which has a website listing locations across the country offering scalp cooling. On breastcancer.org, patients can connect with other survivors who are using scalp cooling to discuss their experiences. See [Table 2](#T2){ref-type="fig"} for more information about patient resources.

HAIR CARE AND RESTRICTIONS DURING THERAPY
=========================================

Patients need to make modifications to their hair care routines if they elect to scalp cool during chemotherapy treatments. Manufacturer instructions regarding hair care vary but often include recommendations regarding frequency and timing, hair product selection, limitations on hair styling, restrictions on using certain hair tools (e.g., hair dryers, curling irons, straightening irons, hot rollers), and brushing and combing. Patients are also usually told to avoid using rubber bands to tie back hair, using head bands, and dyeing their hair ([@A3]; [@A14]).

CONCLUSION
==========

Ms. X received 16 treatments of weekly paclitaxel. An assessment on her final treatment day revealed that she had retained 95% of her hair. Ms. X explained to her providers that having a head of hair that appeared normal made her feel comfortable in social and business situations that are so key to \"normal\" life during cancer therapy. She felt that her scalp cooling experience was a success.

The process and logistics of scalp cooling should be considered before a program is set up. For some clinicians, interventions to decrease alopecia may be of secondary importance to chemotherapy with curative intent. Health-care providers need to understand the evidence behind scalp cooling as well as the data in regards to safety and efficacy. As more patients are requesting its use, advanced practitioners will need to advocate and educate other clinicians and patients about the impact of decreasing the risk or extent of alopecia. The prevention of CIA may have a positive impact on patients' overall quality of life. The use of scalp cooling for patients with solid tumors other than breast cancer, in male patients, and the length of time required for cooling after various chemotherapy regimens needs further study. With more data, providers can offer scalp cooling to a wider selection of patients without reservations.

The authors have no conflicts of interest to disclose.

[^1]: Correspondence to: Lynn Weatherby, RN, BSN, OCN^®^, 3651 Ridge Mill Drive, Hilliard, OH 43026. E-mail: lynn.weatherby\@osumc.edu
